Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis

Rheumatology

Volumn 49, Issue 9, 2010, Pages 1645-1653

  Shimizu, Masaki ^a   Yokoyama, Tadafumi ^a   Yamada, Keiko ^b   Kaneda, Hisashi ^c   Wada, Hideo ^d   Wada, Taizo ^a   Toma, Tomoko ^a   Ohta, Kazuhide ^e   Kasahara, Yoshihito ^a   Yachie, Akihiro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b TONAMI GENERAL HOSPITAL   (Japan)

^c Toyama City Hospital   (Japan)

^d Noto General Hospital   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION KANAZAWA MEDICAL CENTER   (Japan)

Author keywords

Interleukin 18; Macrophage activation syndrome; Systemic juvenile idiopathic arthritis

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; FERRITIN; INTERLEUKIN 18; INTERLEUKIN 6; LACTATE DEHYDROGENASE; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION FUNCTION; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS INFECTION; FEMALE; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; HUMAN CELL; INFANT; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; INFANT; INTERLEUKIN-18; MACROPHAGE ACTIVATION SYNDROME; MALE; STATISTICS AS TOPIC; TIME FACTORS;

EID: 77955751173     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq133     Document Type: Article

References (33)

1. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6.
2. Grom AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum 2004;50:689-98.
3. Stéphan JL, Koné-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology 2001; 40:1285-92.
4. Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics 2003;112:e495.
5. Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003;30:401-3.
6. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol 2002;14:548-52.
7. Athreya BH. Is macrophage activation syndrome a new entity? Clin Exp Rheumatol 2002;20:121-3.
8. Ramanan AV. Schneider R. Macrophage activation syndrome-what's in a name! J Rheumatol 2003;30:2513-6.
9. Okamura H, Nagata K, Komatsu T et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 1995;63:3966-72.
10. Okamura H, Tsutsi H, Komatsu T et al. Cloning of a new cytokine that induces IFN-g production by T cells. Nature 1995;378:88-91.
11. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003;73:213-24.
12. Gracie JA. Interleukin-18 as a potential target in inflammatory arthritis. Clin Exp Immunol 2004;136:402-4.
13. Yoshimoto T, Tsutsui H, Tominaga K et al. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci USA 1999;96:13962-6.
14. Maeno N, Takei S, Nomura Y, Imanaka H, Hokonohara M, Miyata K. Highly elevated serum concentrations of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. Arthritis Rheum 2002;46:2539-41.
15. Lotito AP, Campa A, Silva CA, Kiss MH, Mello SB. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J Rheumatol 2007;34:823-30.
16. Jelusić M, Lukić IK, Tambić-Bukovac L et al. Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin Rheumatol 2007;26:1332-4.
17. Petty RE, Southwood TR, Manners P et al. International league of associations for rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
18. Ravelli A, Magni-Manzoni S, Pistorio A et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005;146:598-604.
19. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 2002;44:259-72.
20. Newburger JW, Takahashi M, Gerber MA et al. Diagnosis, treatment and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Pediatrics 2004;114:1708-33.
21. Adachi O, Kawai T, Takeda K et al. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 1998;9:143-50.
22. Okamura H, Kashiwamura S, Tsutsui H, Yoshimoto T, Nakanishi K. Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol 1998;10:259-64.
23. Villanueva J, Lee S, Giannini EH et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005;7:R30-7.
24. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003;142:292-6.
25. Grom AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum 2004;50:689-98.
26. de Jager W, Vastert SJ, Beekman JM et al. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2782-93.
27. Fitzgerald AA, Leclercq SA, Yan A et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005;52:1794-803.
28. Kawashima M, Yamamura M, Taniai M et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2005;52:1794-803.
29. Kawaguchi Y, Terajima H, Harigai M et al. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum 2001;44:1716-7.
30. Cabane J, Michon A, Ziza JM et al. Comparison of long term evolution of adult onset and juvenile onset Still's disease, both followed up for more than 10 years. Ann Rheum Dis 1990;49:283-5.
31. Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idio-pathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006.
32. Bloom BJ, Tucker LB, Miller LC, Schaller JG. Fibrin D-dimer as a marker of disease activity in systemic onset juvenile rheumatoid arthritis. J Rheumatol 1998;25: 1620-5.
33. Bleesing J, Prada A, Siegel DM et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:965-71.